secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276022
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics reports Q3 net loss of $2.1M; IND accepted for COYA 302 in ALS
--------------------------------------------------------------------------------

- Net loss of $2.1M for Q3 2025 improved from $4.0M loss in Q3 2024; cash and equivalents at $28.1M.
- FDA accepted IND for COYA 302 in ALS; ALSTARS Phase 2 trial launched with up to 25 sites.
- Closed $23.0M upsized public offering; cash runway extended into second half of 2027.
- Received $4.2M milestone from Dr. Reddy's for IND approval; additional $4.2M due on first dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/0001193125-25-276022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312525276022/coya-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer